Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Tissue Transglutaminase in Marmoset Experimental Multiple Sclerosis: Discrepancy between White and Grey Matter.
Isolation of bacterial plasmid-related replication-associated circular DNA from a serum sample of a multiple sclerosis patient.
Removal of access to alemtuzumab for patients with aggressive multiple sclerosis.
NLRP3 Inflammasome and MS/EAE.
EXPRESSION OF CONCERN: The American Academy of Neurology's Top Five Choosing Wisely recommendations.
Dimethyl fumarate : a Janus-faced substance?
Simplified scoring of the Actionable 8-item screening questionnaire for neurogenic bladder overactivity in multiple sclerosis: a comparative analysis of test performance at different cut-off points.
[Treatment of transplantation of NT-3 gene modified olfactory ensheathing cells on experimental autoimmune encephalomyelitis in rats].
Effects of magnetization transfer on T1 contrast in human brain white matter.
Reduced Myelin Water in the White Matter Tracts of Patients with Niemann-Pick Disease Type C.
A Sphingosine-1-Phosphate Receptor 1-Directed Agonist Reduces Central Nervous System Inflammation in a Plasmacytoid Dendritic Cell-Dependent Manner.
Better look (and think) twice-TNF-alpha-inhibition and multiple sclerosis.
Neuromuscular adaptations to long-term progressive resistance training translates to improved functional capacity for people with multiple sclerosis and is maintained at follow-up.
Purified human C1-esterase inhibitor is safe in acute relapses of neuromyelitis optica.
A questionnaire survey comparing the educational priorities of patients and medical students in the management of multiple sclerosis.
Establishing pathological cut-offs of brain atrophy rates in multiple sclerosis.
Occupational attainment as a marker of cognitive reserve in multiple sclerosis.
Cladribine tablets for the treatment of relapsing-remitting multiple sclerosis.
CD44 Deficiency Contributes to Enhanced Experimental Autoimmune Encephalomyelitis: A Role in Immune Cells and Vascular Cells of the Blood-Brain Barrier.
Quality of life in patients with multiple sclerosis.
Environmental factors acting during development to influence MS risk: insights from animal studies.
MRI measures should be a primary outcome endpoint in Phase III randomized, controlled trials in multiple sclerosis: Yes.
Signaling networks in MS: A systems-based approach to developing new pharmacological therapies.
Habitual Functional Electrical Stimulation Therapy Improves Gait Kinematics and Walking Performance, but Not Patient-Reported Functional Outcomes, of People with Multiple Sclerosis who Present with Foot-Drop.
Differential expression of multiple kallikreins in a viral model of multiple sclerosis points to unique roles in the innate and adaptive immune response.

Pages